• Customer Care
  • (888) 123-4567

Our Science

At Rise Therapeutics, we pioneer precision immunotherapy by integrating innovative scientific discovery with synthetic biology methodologies that enable oral drug delivery to develop first-in-class Oral Immune BioModulators. Our proprietary platform enables the targeted reprogramming of dendritic cells—key regulators of immune function—restoring immune balance in autoimmune diseases and cancer. Through rational drug design, we create breakthrough therapies that modulate immune pathways with unprecedented precision and control, now being validated in human clinical trials.

Innovation

Merging our understanding of immune therapy with cutting-edge oral drug delivery methodologies, Rise Therapeutics is pioneering precision immunotherapy to treat a broad range of clinical indications. We utilize synthetic biology methodologies combined with strong product development experience and state-of-the-art clinical GMP manufacturing infrastructure allowing us to be a differentiated industry leader in novel immune medicine development. Currently advancing through clinical validation studies, our breakthrough therapies hold the potential to revolutionize immunotherapy.

 

Immunology

Unlocking Immune Programming

Rise Therapeutics’ Oral Immune BioModulators represent a paradigm shift in immunotherapy, utilizing the gut as a critical gateway to systemic immune function. Our approach focuses on selected targeting of dendritic cells (DCs)—key orchestrators of immune surveillance, activation, and tolerance. By selectively reprogramming DCs, we drive controlled immune responses, counteracting the maladaptive signaling seen in autoimmunity, chronic inflammation, and cancer.

This targeted intervention restores immune balance, offering unprecedented specificity in treating complex immune-driven diseases.

Dendritic cell control

From science to patients

We focus on the interface between the innate and adaptive immune systems, and on key cellular regulators such as dendritic cells. Dendritic cells play a critical role in controlling the modulation of our immune system, from surveying and mounting a response against intruders to training the body to tolerate its beneficial commensal ecosystem and host tissues.

Our scientific founders discovered key dendritic cell control mechanisms, including the modulating targets and their natural ligands, enabling rational drug design to tailor immune repertoire ‘on demand’ via our proprietary Oral Immune Biomodulators. For example, induction of T cells (Tregs) cells can have beneficial effects in treating autoimmune disease and driving the correct type of effector T cell (Teff) can eradicate cancer.

We validate our targets extensively through state of the art in vitro and in vivo models recapitulating human disease and thoroughly scrutinize our drug candidates via non-clinical safety studies. The extensive preclinical validation work performed by our team enables us to construct the best possible medicines for patients with high success rates in human clinical evaluation.

Synthetic Biology

Targeted, oral drug delivery

Synthetic biology utilizes rational design and construction of natural biological systems to develop novel therapies and biotechnological solutions. At Rise Therapeutics, we use proprietary approaches to engineer living medicine products which direct targeted biological response. Using synthetic biology, Rise Therapeutics has pioneered receptor specific dendritic cell engagement, which, combined with a proprietary oral drug delivery platform, enables precise immune modulation via our novel Oral Immune BioModulators. This innovative technology transforms the way we engage the immune system, unlocking new possibilities in immunotherapy. These products have broad applications in treating human disease.